Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: GXV813
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals